# Valvulopathies aortiques asymptomatiques: Opérons nous trop tard?



Jean-Luc MONIN, Alain BERREBI, Emmanuel LANSAC, Mathieu DEBAUCHEZ.

Institut Mutualiste Montsouris, Paris, FRANCE



## My disclosures related to this talk

None






## RAC: Cas clinique N°1

- Homme de 73 ans
- Pèse 75 kg pour 170 cm (SC= 1,86 m²)
- ATL fémorale superficielle (G) 1992
- Asymptomatique dans la vie courante
- Voyage au Mexique réservé (dans 1 mois)






#### Valve aortique calcifiée / HVG





#### Insuffisance aortique?

www.imm.fr






89 bpm




#### Aorte initiale non dilatée








#### HVG (concentrique?)








#### Anneau aortique large






#### Probable bicuspidie (forme rare)





#### www.imm.fr






88 bpm



www.imm.fr





89 bpm




#### Simpson biplan (Semi)-Auto








## Volume TD-VG indexé = 71 ml/m<sup>2</sup>













#### IAo: Incidence apicale 3C








#### Débit cardiaque augmenté








#### PHT (relativement) court





# 


#### Vmax = 5.4 m/s





# 


#### Vmax = 5.6 m/s







#### Parasternale droite: pas mieux







## Homme, 73 ans asymptomatique

- Valve aortique sévèrement calcifiée
- HVG concentrique, Fraction d'éjection VG = 66%
- IAo: QC = 10 I/min, PHT = 270 ms
- RAC: Vmax = 5,6 m/s, GM = 75 mmHg, SVA: 0,9 cm<sup>2</sup>





## Valvulopathie aortique

- A. Rétrécissement aortique sévère
- B. Insuffisance aortique sévère
- C. Maladie aortique sévère





## Valvulopathie aortique

- A. Rétrécissement aortique sévère
- B. Insuffisance aortique sévère
- C. Maladie aortique sévère





#### Quel examen complémentaire?

- A. ECG d'effort
- B. Echographie d'effort
- C. Scanner cardiaque
- D. Coronarographie





#### Quel examen complémentaire?

#### A. ECG d'effort

- B. Echographie d'effort
- C. Scanner cardiaque
- D. Coronarographie

Exercise testing (ECG) is recommended in physically active patients for unmasking symptoms and for risk stratification of asymptomatic patients with severe AS

2017 ESC/EACTS Guidelines for the management of valvular heart disease

European Heart Journal. 2017; 38: 2739-91



Protocole:

LDR Cycloergomètre

Motif d'arrêt :

Fatigue musculaire du patient

#### Tableau des données d'effort

Phase	Palier	Durée pal.	Charge (W)	tours (tpm)	FC (/min)	TA (mmHg)	Commentaire
PRE-TEST		00:38	0	0	78		
EFFORT	PALIER 1	00:04	0	0	80		
	PALIER 2	02:00	88	57	122	189/89	
	PALIER 3	00:17	93	57	126	219/94	
RECUP.		06:15	0	0	90	163/82	

Fc repos:

78 /min

FC max:

126 /min soit 85 % de la FMT calculée à 147 /min Réserve FC utilisée: 69 %

FC fin de récup:

90 /min

TA repos:

--/-- mmHg

TA max:

219/94 mmHg

TA fin de récup :

--/-- mmHg

ST max:

-0.80 mm, 0.00 mV/s en II; EFFORT PALIER 2 02:00

Durée de l'effort :

2:20 min

Charge maximale: 93 Watt = 5.0 METS

PWC 130 1.25 W/kg

PWC 150 -- W/kg

#### CONCLUSION:

TEST D EFFORT MENE A 86 % DE LA FMT POUR UNE CHARGE DE 93 WATTS NEGATIF CLINIQUEMENT ET ELECTRIQUEMENT HTA DE REPOS CONTEXTE ANXIETE TROULBE DE REPOLARISATION EN RECUPERATION AVEC st SOUS DECLAE A -0,8 MM



## Quelle prise en charge?

- A. Surveillance CLIN + Echo à 6 mois
- B. TAVI
- C. RVA chirurgical





Important: The previous additive <sup>1</sup> and logistic <sup>2</sup> EuroSCORE models are out of date. A new model has been prepared from fresh data and is launched at the 2011 EACTS meeting in Lisbon. The model is called EuroSCORE II <sup>3</sup> - this online calculator has been updated to use this new model. If you need to calculate the older "additive" or "logistic" EuroSCORE please visit the old calculator by <u>clicking here</u>.

	Patient related factors			Cardiac related factors	
Age <sup>1</sup> (years)	75	0.46	NYHA		0
Gender	male 🗘	0	CCS class 4 angina	no 🗘	0
Renal impairment <sup>2</sup> See calculator below for creatinine clearance	normal (CC >85ml/min)	0	LV function	good (LVEF > 50%)	0
Extracardiac arteriopathy <sup>3</sup>	yes 🗘	.5360268	Recent MI <sup>9</sup>	no 💲	0
Poor mobility <sup>4</sup>	no 💸	0	Pulmonary hypertension <sup>10</sup>	no	0
Previous cardiac surgery	no 💸	0		Operation related factors	
Chronic lung disease <sup>5</sup>	no 🗘	0	Urgency <sup>11</sup>	elective	0
Active endocarditis	no 😊	0	Weight of the intervention <sup>12</sup>	single non CABG 😊	.0062118
Critical preoperative state <sup>7</sup>	no 🗘	0	Surgery on thoracic aorta	no 🗘	0
Diabetes on insulin	no 💲	0			
EuroSCORE II	1.30 %				
Note: This is the 2011 EuroSCORE II	Calculate Clear				



## Quelle prise en charge?

- A. Surveillance CLIN + Echo à 6 mois
- B. TAVI
- C. RVA chirurgical
- Vmax > 5,5 m/s
- Age <75 ans, faible risque opératoire
- Probable bicuspidie (confirmée à l'intervention)
- Longévité des prothèses « TAVI » après 5 ans ?

2017 ESC/EACTS Guidelines for the management of valvular heart disease


European Heart Journal. 2017; 38: 2739-91





#### Early surgery:

- Risk of sudden death ++
- Myocardial fibrosis
- Postop. LV dysfunction
- Death on the waiting list
- Cardiologist's anxiety (!)



#### Watchful waiting:

- Operative risk ++
- Valve related morbidity:
  - 2-3%/ year
- Endocarditis, thrombosis,
   bleeding

Rosenhek et al. Eur Heart J. 2002;23:1417-21



## The patient with asymptomatic AS

- 1. The risk of sudden death
- 2. The risk of myocardial fibrosis
- 3. Relevant cutoffs for Vmax/LVEF?
- 4. Exercise testing
- 5. Role for 2D-strain imaging?
- 6. What do the Guidelines tell us?





## The patient with asymptomatic AS

# Sudden death vs Operative risk





# Asymptomatic AS: Risk of sudden death Without preceding symptom?

Author (Year)	N patients	FU (months)	AS severity	Sudden death (annual rate, %)
Otto (1997)	123	30	V <sub>max</sub> > 2.5 m/s	0
Amato (2001)	66	15	AVA < 1.0 cm <sup>2</sup>	4.8
Monin (2009)	211	22	V <sub>max</sub> > 3.0 m/s	0.4
Rosenhek (2010)	116	41	V <sub>max</sub> > 5.0 m/s	0.3
Lancellotti (2010)	126	20	AVA < 1.2 cm <sup>2</sup>	0.1
Maréchaux (2010)	135	20	AVA < 1.5 cm <sup>2</sup>	0





#### Sudden death in patients with severe AS: Data from the CURRENT AS Registry

- www.imm.fr
  - Retrospective analysis (2003-2011) of 3815 consecutive patients (Vmax> 4.0 m/s, MPG >40 mmHg, or AVA < 1.0 cm²) Mean age =78 years, 38% of males</li>
  - Median follow-up duration = 3.6 years (>2 years in 93%)

	Whole Cohort	Symptomatic	Asymptomatic	
Variables	N=3815	N=2005	N=1808	P Value
Echocardiographic variables				
V <sub>max</sub> , m/s	4.1±0.9	4.3±0.9	3.9±0.8	<0.001
V <sub>max</sub> ≥5 m/s*	698 (18%)	490 (24%)	207 (11%)	<0.001
V <sub>max</sub> ≥4 m/s	2185 (57%)	1320 (66%)	864 (48%)	<0.001
Peak aortic PG, mm Hg	72±32	78±33	65±28	<0.001
Mean aortic PG, mm Hg	41±20	45±21	36±17	<0.001
AVA (equation of continuity), cm <sup>2</sup>	0.72±0.18	0.67±0.19	0.77±0.17	<0.001

#### **RESULTS: Among 82 asymptomatic patients experiencing sudden death:**

- 66% of patients (n=54) died abruptly without any preceding symptoms
- 65% of these sudden deaths occurred within 3 months of the last clinical follow-up visit






# Sudden death in patients with severe AS: Data from the CURRENT AS Registry

www.imm.fr

Asymptomatic patients : cumulative 5-year incidence of sudden death (censored at AVR) = 7.2% (1.4%/year)

### Independent risk factors for sudden death:

- Hemodialysis (HR 3.63; 95% CI 2.42-5.43)
- Prior myocardial infarction (HR 2.11; 95% CI 1.28-3.50)
- Peak aortic jet velocity ≥ 5 m/s
   (HR 1.76; 95% CI 1.12-2.78)
- <u>LV ejection fraction < 60%</u> (HR 1.52; 95% CI1.08-2.14).
- Body mass index < 22 (HR 1.51; 95% CI 1.03-2.21)





Taniguchi et al. J Am Heart Assoc. 2018; 7:e008397.



#### The Society of Thoracic Surgeons National Database 2018 Annual Report

Jacobs et al. Ann Thorac Surg. 2018; 106: 1603-11



Table 1. STS National Database Participation				
Variable	STS Adult Cardiac Surgery Database <sup>a</sup>			
Participants <sup>c</sup> in United States	1,079			
Hospitals <sup>d</sup> in United States	1,120			
Surgeons in United States	2,966			
Operations <sup>e</sup> in United States	6,610,348			
States in United States	50 states and Washington, DC			
Estimated penetration at the hospital level in United States	>90%-95% of hospitals that perform adult hear operations in the United States <sup>f</sup>			
Percentage of programs in United States and Canada that consented to voluntarily publicly report (as of October 1, 2018)	65.4			
Total countries (including United States)i	11			
Participants <sup>c</sup> outside United States	32			
Hospitals <sup>d</sup> outside United States	32			
Surgeons outside United States	171			
Operations <sup>e</sup> outside United States	62,291			
Total participants <sup>c</sup>	1,111			
Total hospitals <sup>d</sup>	1,152			
Total surgeons	3,137			
Total operations <sup>e</sup>	6,672,639			



#### The Society of Thoracic Surgeons National Database 2018 Annual Report

www.imm.fr

Selected Outcomes of the More Commonly Performed Adult Cardiac Surgical Procedures

in Calendar Year 2016

Variable	AVR	AVR + CABG
No. of operations	28,037	17,196
Mortality, %		
In-hospital mortality	1.6	2.7
Operative mortality <sup>b</sup>	2,2	3.3
Major morbidity, %		
Reoperation <sup>c</sup>	4.8	6.2
DSWI/mediastinitis	0.1	0.3
Permanent stroke	1.4	2.2
Prolonged ventilation >24 hours	6.6	11.9
Renal failure	1.9	3.6
New-onset atrial fibrillation	31.3	39.1
Readmission ≤ 30 days of discharge	9.8	12,2
Postoperative hospital LOS, days		
Mean	7.0	8.4
Median	6.0	7.0





#### The patient with asymptomatic AS

#### Myocardial fibrosis?







#### Myocardial Scar and Mortality in Severe Aortic Stenosis (BSCMR Valve Consortium)

Observational study (6 UK cardiothoracic centers, January 2003 to May 2015):

- 674 patients with severe AS (aged 75±14 years; 63% male; MPG: 46±18 mmHg; LVEF: 61±17%) listed for AVR or TAVI.
- Patients underwent CMR for LV volumes, EF and scar quantification. Myocardial scar was categorized into 3 patterns: none, infarct, or non-infarct patterns










#### **Myocardial Scar and Mortality in Severe Aortic Stenosis (BSCMR Valve Consortium)**

www.imm.fr

- Management: surgical AVR (n=399) or TAVI (n=275).
- 145 patients died (21.5%) during followup (median, 3.6 years)

#### **Independent factors for all-cause mortality:**

- Age
- (HR,1.50; 95% CI, 1.11-2.04; P =0.009, scaled by epochs of 10 years)
- STS score
- (HR, 1.12; 95% CI, 1.03–1.22; P =0.007)
- Scar presence assessed by CMR(HR, 2.39; 95% CI, 1.40–4.05; P =0.001)








#### **Myocardial Scar and Mortality in Severe Aortic Stenosis (BSCMR Valve Consortium)**

#### Myocardial scar independently predicted:


- All-cause mortality(26.4% versus 12.9%; P < 0.001)</li>
- Cardiovascular mortality(15.0% versus 4.8%; P < 0.001)</li>
- Every 1% increase in LV myocardial scar burden was associated with 8% higher cardiovascular mortality (HR, 1.08; 95% CI, 1.01–1.17; P <0.001)








#### Preserved LVEF vs. Impaired longitudinal strain, linked to myocardial fibrosis





24/09/2012-11:52:38

GLPS_LAX	-17.1 %	AVC_AUTO	378 msec
GLPS_A4C	-16.8 %	HR_ApLAX	89.9 bpm
GLPS_A2C	-14.5 %		
GLPS_Avg	-16.1 %		

Weidemann et al. Circulation. 2009; 120: 577-84





#### The patient with asymptomatic AS

# **Cutoffs for Vmax:**What is critical AS?





**Background:** The definition of critical AS remains unclear: Vmax> 5-m/s (USA) vs. 5.5 m/s (Europe). NB: ≈20% of patients with severe AS are in this range. **Methods:** 1140 patients with preserved LVEF, AVA ≤ 1 cm<sup>2</sup> and Vmax ≥ 4 m/s were divided into 4 groups:


Variable	Vmax 4-4.49 m/s (n=460)	Vmax 4.5-4.99 m/s (n=328)	Vmax 5-5.49 m/s (n=220)	Vmax ≥5.5 m/s (n=132)	<i>P</i> Value
Demographics, baseline data, and symptoms					
Age, y	75±11	74±11	74±12	74±12	0.538
Male sex, n (%)	231 (51.2%)	188 (57.7%)	109 (49.8%)	64 (48.9%)	0.162
Body surface area, m <sup>2</sup>	1.88±0.2	1.89±0.2	1.87±0.2	1.87±0.2	0.464
Hemoglobin, g/dL*	12.8±2.4	12.8±1.9	12.9±1.8	12.7±1.8	0.746
Creatinine, µmol/L†	100±58	103±60	103±62	102±46	0.873
NYHA, n (%)					
1–2	353 (76.7%)	237 (72.3%)	162 (73.6%)	103 (78%)	
					0.404
3–4	107 (23.3%)	91 (27.7%)	58 (26.4%)	29 (22%)	





#### After adjustment for covariates (including surgery):


- No difference in mortality between Vmax 4-4.49 m/s vs. Vmax 4.5-4.99 m/s (P =0.64).
- Both Vmax 5-5.49 m/s and Vmax ≥ 5.5 m/s exhibited significant excess mortality vs. Vmax < 5 m/s








Asymptomatic/minimally symptomatic patients with severe AS: Survival curves adjusted for age, sex, BSA, hypertension, NYHA class, CAD, atrial fibrillation, comorbidity index, LVEF









Multi variable analysis: Asymptomatic patients with Vmax ≥ 5 m/s have a 2-fold increase in mortality risk after adjustment for AV surgery

Vmax	HR	CI	P value		
Model 1: Adjusted: for age, sex, BSA, hypertension, CAD, atrial fibrillation, comorbidity index, LVEF					
Vmax <5 m/s	Reference				
Vmax >5 m/s	1.85	1.25-2.71	0.002		
Model 2: Adjusted for all variables in Model 1 + AV surgery (time dependent)					
Vmax <5 m/s	Reference				
Vmax >5 m/s	1.98	1.47-2.68	<0.001		





#### The patient with asymptomatic AS

# Cutoffs for LVEF: LV systolic dysfunction in AS?





- Multicenter study: Amiens, Lille, Brussels
- 1 678 patients with severe AS, LVEF ≥50% No or minimal symptoms
- Population divided into 3 groups: LVEF ≥60%, LVEF 55%-59% and LVEF<55%</li>

TABLE 1 Baseline Demographic, Clinical, and Echocardiographic Characteristics of the Study Population With Asymptomatic and Minimally Symptomatic Severe Aortic Stenosis According to LVEF


	LVEF ≥60% (n = 1,108)	LVEF 55%-59% (n = 331)	LVEF <55% (n = 239)	p Value
Demographic data and symptoms				
Age, yrs	$75.8 \pm 10.3$	$75.8 \pm 10.7$	$76.3 \pm 10.3$	0.709
Males	517 (46.7)	181 (54.7)*	138 (57.7)*	0.001
Aortic valve				
Aortic valve area, cm <sup>2</sup>	0.74 (0.60, 0.89)	0.73 (0.58, 0.86)	0.75 (0.61, 0.90)	0.387
Peak aortic jet velocity, m/s	4.3 (3.8, 4.8)	4.2 (3.7, 4.7)	4 (3.4, 4.7)†	0.008
Transaortic mean pressure gradient, mm Hg	46 (34, 57)	44 (34, 57)	41 (30, 54)*	0.001
Indexed stroke volume, ml/m²	40 (32, 46)	38 (33, 44)	36 (29, 43)*	0.011
Left ventricular function				
LV end-diastolic diameter, mm	46 (41, 51)	47 (42, 53)*	49 (43, 53)†	<0.001
LV end-systolic diameter, mm	27 (23, 31)	30 (26, 35)†	33 (28, 38)†	<0.001
LV end-diastolic volume, ml	100 (79, 135)	117 (91, 154)†	123 (95, 157)†	0.001
LV end-systolic volume, ml	33 (23, 44)	48 (37, 62)†	57 (45, 72)†	<0.001
Ejection fraction	68 (65, 73)	58 (57, 59)†	53 (51, 54)†	<0.001
sPAP, mm Hg	30 (25, 37)	30 (25, 38)	32 (25, 40)	0.066
GLS‡	-17 ± 2	$-16 \pm 3$	-15 ± 4*	0.007



49




RESULTS: LVEF <55% (14% of study population) was associated with a >2-fold increase in the risk of all-cause mortality










Patients with LVEF <55% managed conservatively displayed significant excess mortality, even after covariate adjustment (adjusted HR: 2.44 [1.51 to 3.94]; p < 0.001)







Patients with preoperative LVEF <55% who underwent SAVR within 3 months also displayed significant excess mortality (adjusted HR: 2.51 [1.58 to 4.00]; p < 0.001)





#### The patient with asymptomatic AS


# Exercise testing: What is really useful?






## Exercise-Echo in asymptomatic (moderate-severe) aortic stenosis

N= 69 patients. After 15±7 months of FU: 2 patients developed symptoms, 2 were hospitalized for CHF, 12 underwent AVR (combined with CABG in 4) and 3 died (2 from sudden death and 1 in the postoperative period)






Incremental prognostic value of Exercise Echo over Rest/ Exercise test: OK Concerns: mainly moderate AS at baseline; events mostly driven by AVR +++






#### Usefulness of *Exercise Echocardiography* in asymptomatic aortic stenosis

135 asymptomatic patients with moderate/ severe AS and normal standard exercise test






The technical challenge of Doppler measurements at peak exercise may limit their widespread use +++





## Prognostic value of Exercise-Echo in asymptomatic patients with AS

148 consecutive patients (66±15 years; 74% males) with pure, isolated, asymptomatic AS, LVEF ≥50% and SPAP <50 mm Hg underwent symptom-limited exercise echocardiography




- (A) Strong correlation between MPG at rest and MPG at peak exercise
- (B) No correlation between MPG at rest and changes in MPG during exercise





## Prognostic value of Exercise-Echo in asymptomatic patients with AS

After adjustment for age, sex, and LVEF, MPG at rest was predictive of outcome (HR: 1.07; 95% CI: 1.04 to 1.10; p < 0.0001)









## Prognostic value of Exercise-Echo in asymptomatic patients with AS

Neither MPG increase >20 mm Hg nor peak SPAP >60 mm Hg was predictive of the occurrence of AS-related events or aortic valve replacement (all p >0.20)









#### The patient with asymptomatic AS

#### What's the role of BNP?





#### Plasma Brain Natriuretic Peptide Concentration: Impact of Age and Gender

- In 2 042 randomly selected residents of Olmsted County (Minnesota) >44 years old, BNP (Shionogi and Biosite assays), Doppler echocardiography, and medical record review were performed.
- A normal subset of subjects (n =767) in sinus rhythm, without cardiovascular, renal or pulmonary disease or diabetes; without cardiovascular medications and with normal systolic, diastolic, and valvular function was identified.

**Table 1.** Plasma BNP (Biosite [BNP-B] and Shionogi [BNP-S] Assays) by Age and Gender in Normal Subjects

	A	Age 45-54	1	Age 55-64		Age 65-74		Age 75-83
Gender BNP	n	Median (25th, 75th)	n	Median (25th, 75th)	n	Median (25th, 75th)	n	Median (25th, 75th)
Women								
Biosite	180	18 (10, 32)	135	27 (15, 43)	56	29 (19, 52)	17	67 (28, 89)
Shionogi	194	28 (13, 55)	141	32 (18, 68)	59	45 (20, 111)	18	58 (26, 172)
Men				a transfer de la constante de				
Biosite	181	7 (3, 13)	111	11 (5, 20)	40	18 (7, 37)	2	21 (17, 24)
Shionogi	193	17 (9, 34)	118	31 (14, 49)	42	28 (10, 58)	2	38 (31, 44)

The median 25th and 75th percentiles are shown. BNP = brain natriuretic peptide.





#### BNP clinical activation in aortic stenosis: Impact on long-term survival

- <u>Definition</u>: BNP Ratio = measured BNP/maximal normal BNP value specific to age and sex; BNP Ratio >1 defined BNP clinical activation
- Hypothesis: Link between BNP Ratio and mortality in 1 953 consecutive patients with at least moderate AS

	Whole cohort (n= 1 953)	Asymptomatic isolated AS (n= 565)
Age (years)	76±12	74±13
Male (%)	55	55
Symptoms, n (%)	1 165 (60)	0
BNP (pg/ml)	252 (98-592)	138 (58-324)
BNP ratio	2,5 (1,0-5,7)	1,4 (0,6-3,1)
Vmax (m/s)	3,8±1,0	3,9±1,0
LVEF (%)	57±15	65±7






## BNP clinical activation in aortic stenosis: Impact on long-term survival

 Link between BNP Ratio and mortality in 1 953 consecutive patients with at least moderate aortic stenosis

- \*HR Adjusted for:
- age, sex,
- body surface area,
- atrial fibrillation,
- Charlson score index,
- symptoms,
- creatinine level,
- hemoglobin level,
- systolic blood pressure
- indexed aortic valve area,
- LV ejection fraction,
- aortic valve replacement as timedependent variable








## BNP clinical activation in aortic stenosis: Impact on long-term survival

 Link between BNP Ratio and overall survival in 565 asymptomatic patients with at least moderate aortic stenosis, normal LV ejection fraction and no previous AMI



- BNP clinical activation is associated with excess longterm mortality incrementally and independently of all baseline characteristics, even in asymptomatic patients
- Higher mortality with higher BNP clinical activation emphasizes the need of appropriate clinical interpretation of BNP levels according to age/gender



#### Risk score for predicting outcome in patients with asymptomatic aortic stenosis

- Prospective observational study, single center (FR): 107 patients with asymptomatic AS (72 years [63-77]; 35 women; Vmax: 4.1 m/s [3.5-4.4]).
- Predefined end points for assessing outcome: occurrence within 24 months of death or AV replacement necessitated by symptoms.

Variable at baseline	Whole population (n= 104)	Remained asymptomatic (n= 42)	Endpoint ≤ 24 months (n=62)	p value
Valve area, cm²	0.9 [0.8-1.1]	1.1 [1.0-1.3]	0.8 [0.7-1.0]	0.0001
Indexed area, cm²	0.5 [0.4-0.6]	0.6 [0.5-0.7]	0.5 [0.4-0.5]	0.0001
Baseline BNP, pg/ml	58 [30-111]	30 [14-64]	83 [43-165]	0.0001
BNP (2), pg/ml	66 [32-173]	36 [16-71]	161 [64-242]	0.0001





#### Risk score for predicting outcome in patients with asymptomatic aortic stenosis

Variables independently associated with outcome were used to build a score that was validated in an independent cohort of 107 patients from Belgium

Variable at baseline	Odds ratio	95% confidence interval	p value
Baseline serum BNP	3.9	1.8 - 8.1	0.0001
Baseline Peak aortic -jet velocity	6.2	2.1 - 17.9	0.001
Female gender	5.2	1.5 - 18.6	0.012


Score = [Vmax (m/s) x 2] + [Nat. Log BNP x 1.5] + 1.5 (female gender)





#### Risk score for predicting outcome in patients with asymptomatic aortic stenosis

Event-free survival after 20 months: 80% for patients within the 1st score quartile vs. 7% for the 4th quartile





#### The patient with asymptomatic AS

What's the role of 2D-strain?





Valvular heart disease

# Alterations in multidirectional myocardial functions in patients with aortic stenosis and preserved ejection fraction: a two-dimensional speckle tracking analysis

Arnold C.T. Ng<sup>1,2†</sup>, Victoria Delgado<sup>1†</sup>, Matteo Bertini<sup>1</sup>, Marie Louisa Antoni<sup>1</sup>, Rutger J. van Bommel<sup>1</sup>, Eva P.M. van Rijnsoever<sup>1</sup>, Frank van der Kley<sup>1</sup>, See Hooi Ewe<sup>1</sup>, Tomasz Witkowski<sup>1</sup>, Dominique Auger<sup>1</sup>, Gaetano Nucifora<sup>1</sup>, Joanne D. Schuijf<sup>1</sup>, Don Poldermans<sup>3</sup>, Dominic Y. Leung<sup>4</sup>, Martin J. Schalij<sup>1</sup>, and Jeroen J. Bax<sup>1\*</sup>


<sup>1</sup>Department of Cardiology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands; <sup>2</sup>Department of Cardiology, Princess Alexandra Hospital, University of Queensland, Brisbane, Queensland, Australia; <sup>3</sup>Department of Anaesthesiology, Erasmus Medical Center, Rotterdam, The Netherlands; and <sup>4</sup>Department of Cardiology, Liverpool Hospital, Sydney, New South Wales, Australia

Received 26 June 2010; revised 31 January 2011; accepted 1 March 2011; online publish-ahead-of-print 29 March 2011



## Alterations in multidirectional strain in AS with preserved ejection fraction (???)


420 patients (age 66±15 years) with aortic sclerosis, mild, moderate, and severe AS with LVEF ≥50%. Multidirectional strain / SR imaging.





## Alterations in multidirectional strain in AS with preserved ejection fraction (???)

Myocardial dysfunction starts in the sub-endocardium (mild AS) to mid-wall (moderate AS) and eventually to transmural dysfunction (severe AS)



Aortic valve area (AS severity) was an independent determinant of multidirectional strain and SR on multiple linear regressions



## Impact of impaired myocardial deformations on exercise tolerance and prognosis in patients with asymptomatic aortic stenosis

Stéphane Lafitte<sup>1\*</sup>, Matthieu Perlant<sup>1</sup>, Patricia Reant<sup>1</sup>, Karim Serri<sup>2</sup>, Herve Douard<sup>1</sup>, Anthony DeMaria<sup>3</sup>, and Raymond Roudaut<sup>1</sup>

<sup>1</sup>Cardiologic Hospital, Pessac and Bordeaux 2 University, France; <sup>2</sup>Sacre Coeur Hospital, University of Montreal, Montreal, Canada; and <sup>3</sup>Division of Cardiology, University of California at San Diego, USA

Received 16 July 2008; accepted after revision10 October 2008

#### Lafitte et al. Eur J Echocardiogr. 2008;10:414-9

#### KEYWORDS

Aortic valvular stenosis; Myocardial contractility; Strain echocardiography; Prognosis Aims As assessed by tissue Doppler velocities, longitudinal contraction is commonly altered at an earlier stage than radial contraction in patients with severe aortic stenosis (AS). However, its relationship to exercise tolerance or to prognosis has not been clearly established. By using two-dimensional (2D) echocardiographic strain, we sought to evaluate values of deformation components in the setting of severe AS and to correlate these values with exercise tolerance and with patients' outcome.

Methods and results Sixty-five asymptomatic patients with severe AS (aortic valve area <1 cm²) were studied by echocardiography and exercise treadmill and were compared with controls. Conventional echographic parameters as well as longitudinal, radial, and circumferential deformations by 2D strain were measured at rest. During exercise treadmill, maximum tolerated workload, maximum heart rate, blood pressure, and EKG ST variations were recorded. Patients were then followed during 12 months. Compared with controls, despite similar ejection fractions, AS patients presented with a significantly lower global longitudinal strain (GLS) ( $-17.8 \pm 3.5$  vs.  $-21.1 \pm 1.8\%$ , P < 0.05) more pronounced in the basal segments (BLS) ( $-12.4 \pm 2.9$  vs.  $-18.4 \pm 2.5\%$ , P < 0.05). No difference was observed in terms of radial or circumferential strains. In a subgroup of AS patients with abnormal response to exercise, GLS and BLS were significantly lower ( $-14.7 \pm 5.1$  vs.  $-19.3 \pm 4.0\%$  and  $-10.7 \pm 2.5$  vs.  $-14.4 \pm 2.1\%$ , P < 0.05). With cut-offs of -18 and -13%, GLS and BLS were able to determine an inadequate exercise response with a sensitivity and specificity of 68 and 75% (AUC 0.77), and 77 and 83% (AUC 0.81), respectively. Finally, patients with a basal strain below -13% presented with more cardiac events in the follow-up.

Conclusion In asymptomatic patients with severe AS, impaired longitudinal contraction assessed by 2D strain is associated with abnormal exercise response and with an increased risk of cardiac events during follow-up.




# Impaired myocardial strain and prognosis in asymptomatic AS

In 65 Pts with asymptomatic AS (strain: GE Medical systems):

- Lower longitudinal strain (- 18 vs. -21%, P < 0.05) vs. Controls despite similar LVEF
- NB: lowest strain-values in basal segments

NB: Circumferential or Radial strain: NS








# Impaired myocardial strain and prognosis in asymptomatic AS

Endpoint: hospitalization for cardiac cause, AV replacement or cardiovascular death within 12 months



# Myocardial deformation in aortic valve stenosis: relation to left ventricular geometry

Dana Cramariuc, 1,2 Eva Gerdts, 1,2 Einar Skulstad Davidsen, Leidulf Segadal, Knut Matre 1

Cramariuc et al. *Heart*. 2010; 96: 106-12

#### ► See Editorial p 95

<sup>1</sup>Institute of Medicine, University of Bergen, Bergen, Norway <sup>2</sup>Department of Heart Disease, Haukeland University Hospital, Bergen, Norway <sup>3</sup>Department of Surgical Sciences, University of Bergen, Bergen, Norway

#### Correspondence to

Dana Cramariuc, Department of Heart Disease, Haukeland University Hospital, NO-5021, Bergen, Norway; dana. cramariuc@helse-bergen.no

Disclosures: Eva Gerdts has received honoraria for occasional lectures at scientific symposia sponsored by Merck/Schering-Plough Pharmaceuticals and as member of the Scientific Steering Committee in the SEAS study.

Accepted 11 August 2009 Published Online First 25 August 2009

#### ABSTRACT

**Objective** To assess left ventricular (LV) strain and displacement and their relations to LV geometry in patients with aortic stenosis (AS).

**Design** Cross-sectional echocardiographic study in patients with AS. Peak circumferential, radial and longitudinal strain, and radial, longitudinal and transverse displacement were measured by 2D speckle tracking. Severity of AS was assessed from energy loss index (ELI). LV hypertrophy was present if LV mass/height<sup>2.7</sup> ≥46.7/49.2 g/m<sup>2.7</sup> in womer/men and concentric LV geometry if relative wall thickness ≥0.43. LV geometry was assessed from LV mass/height<sup>2.7</sup> and relative wall thickness in combination.

**Setting** Department of Heart Disease, Haukeland University Hospital, Bergen, Norway.

**Patients** 70 patients with AS (mean age 73±10 years, 54% women).

Interventions None.

Main outcome measures Association of regional and average LV myocardial strain and displacement with LV geometric pattern and degree of AS.

**Results** Average longitudinal strain was lower in the hypertrophy groups and correlated with higher LV mass index and relative wall thickness. lower stress-corrected

myocardial deformation (ie, thickening and thinning in the radial plane, and shortening and lengthening in the longitudinal and circumferential planes) and thus enabling assessment of regional or global myocardial function. <sup>6-9</sup> Myocardial deformation can be assessed both by tissue Doppler imaging and 2D speckle tracking echocardiography, <sup>10–12</sup>. For this study we chose 2D speckle tracking which is angle-independent and allows faster post-processing and analysis of multiple segments simultaneously. <sup>11</sup> <sup>13</sup>

The aim of this study was to assess the impact of LV geometry on LV strain and displacement in patients with degenerative AS.

#### METHODS


#### Study population

This study was prospectively planned for all patients with degenerative AS who had conventional and 2D speckle tracking echocardiography undertaken at the echocardiography laboratory, Haukeland University Hospital, Bergen, Norway as part of prospective clinical trial protocols in the time period April 2006—October 2007. A total of 70 patients were identified, and all agreed to participate



# Myocardial deformation in AS: Relation to LV geometry


2D-Strain assessed by Speckle Tracking (*GE Healthcare*) in 70 patients with AS and various degrees of LV remodeling






# Myocardial deformation in AS: Relation to LV geometry

Longitudinal Strain was significantly lower in the basal segments in all LV remodeling patterns compared with patients with normal geometry







### Low-Flow, Low-Gradient Severe Aortic Stenosis Despite Normal Ejection Fraction Is Associated With Severe Left Ventricular Dysfunction as Assessed by Speckle-Tracking Echocardiography

### A Multicenter Study

Jérôme Adda, MD; Christopher Mielot, MD; Roch Giorgi, MD, PhD; Frédéric Cransac, MD; Xavier Zirphile, MD; Erwan Donal, MD; Catherine Sportouch-Dukhan, MD; Patricia Réant, MD; Stéphane Laffitte, MD; Stéphane Cade, MD; Yvan Le Dolley, MD; Franck Thuny, MD; Nathalie Touboul, PhD; Cécile Lavoute, PhD; Jean-François Avierinos, MD; Patrizio Lancellotti, MD; Gilbert Habib, MD

Background—Low-flow low-gradient (LFLG) is sometimes observed in severe aortic stenosis (AS) despite normal ejection fraction, but its frequency and mechanisms are still debated. We aimed to describe the characteristics of patients with LFLG AS and assess the presence of longitudinal left ventricular dysfunction in these patients.

Methods and Results—In a multicenter prospective study, 340 consecutive patients with severe AS and normal ejection fraction were studied. Longitudinal left ventricular function was assessed by 2D-strain and global afterload by valvulo-arterial impedance. Patients were classified according to flow and gradient: low flow was defined as a stroke volume index ≤35 mL/m², low gradient as a mean gradient ≤40 mm Hg. Most patients (n=258, 75.9%) presented with high-gradient AS, and 82 patients (24.1%) with low-gradient AS. Among the latter, 52 (15.3%) presented with normal flow and low gradient and 30 (8.8%) with LFLG. As compared with normal flow and low gradient, patients with LFLG had more severe AS (aortic valve area=0.7±0.12 cm² versus 0.86±0.14 cm²), higher valvulo-arterial impedance (5.5±1.1 versus 4±0.8 mm Hg/mL/m²), and worse longitudinal left ventricular function (basal longitudinal strain=−11.6±3.4 versus −14.8±3%; P<0.001 for all).

Conclusions—LFLG AS is observed in 9% of patients with severe AS and normal ejection fraction and is associated with high global afterload and reduced longitudinal systolic function. Patients with normal-flow low-gradient AS are more frequent and present with less severe AS, normal afterload, and less severe longitudinal dysfunction. Severe left ventricular longitudinal dysfunction is a new explanation to the concept of LFLG AS. (Circ Cardiovasc Imaging. 2012;5:27-35.)



## Bas débit/ bas gradient paradoxal : Altération de la fonction longitudinale

Etude multicentrique, N= 340 Pts, SAo < 0.6 cm<sup>2</sup>/m<sup>2</sup> avec FEVG >50%

Strain (2D) Longitudinal	Débit normal/ Haut Gradient N= 213, 63%	Bas débit/ Haut Gradient N= 45, 13%	Débit normal/ Bas Gradient N= 52, 15%	Bas débit/ Bas Gradient N= 30, 9%
Strain global (%)	-17±3	-14±4 ***	-17±4	-16±4
Strain apical (%)	-22±6	-20±5 *	-21±6	-20±7
Strain médian(%)	-16±3	-14±3 ***	-17±3	-14±3 §
Strain basal (%)	-14±3	-11±3 ***	-15±3	-12±3 *§§





## Relationship between Longitudinal Strain and Symptomatic Status in Aortic Stenosis

David Attias, MD, Laurent Macron, MD, Julien Dreyfus, MD, Jean-Luc Monin, MD, PhD, Eric Brochet, MD, Laurent Lepage, MD, Guillaume Hekimian, MD, Bernard Iung, MD, Alec Vahanian, MD, and David Messika-Zeitoun, MD, PhD, Paris, France

Background: Global longitudinal strain (GLS) and basal longitudinal strain (BLS) assessed using two-dimensional speckle-tracking imaging have been proposed as subtle markers of left ventricular (LV) systolic dysfunction with potential prognostic value in patients with aortic stenosis (AS). The aim of this study was to evaluate the relationship between longitudinal strain and symptomatic status in patients with AS.

*Methods:* GLS and BLS were measured in 171 patients with pure, isolated, at least mild AS prospectively enrolled at two institutions. The population was divided into four groups: asymptomatic nonsevere AS (n = 55), asymptomatic severe AS with preserved LV ejection fraction (LVEF;  $\geq 50\%$ ) (n = 37), symptomatic severe AS with preserved LVEF (n = 60), and severe AS with reduced LVEF (n = 50%) n = 19.

Results: GLS was significantly different among the four groups (P < .0001), but the difference was due mainly to patients with reduced LVEFs. In addition, there was an important overlap among the groups, and in multivariate analysis, after adjustment for age, gender, AS severity, and LVEF, GLS was not an independent predictor of symptomatic status (P = .07). BLS was also significantly different among the four groups (P < .0001) but in contrast was independently associated with symptomatic status (P < .0001). However, as for GLS, there was an important overlap between groups and differences were close to intraobserver or interobserver variability (1.3  $\pm$  1.1% and 2.0  $\pm$  1.6%, respectively).


Attias et al. J Am Soc Echocardiogr. 2013; 8: 868-74



# Relationship between longitudinal strain and symptomatic status in AS

GLS and BLS measured in 171 patients with pure, at least mild AS prospectively enrolled at two institutions

- BLS was independently associated with symptomatic status in contrast to GLS.
- However: important overlap between groups; differences close to measurements' reproducibility
- Longitudinal strain, at least as a single criterion, should be interpreted with caution in the decision-making process in asymptomatic/ severe AS







# Basal longitudinal strain predicts future aortic valve replacement in asymptomatic patients with aortic stenosis

Helle Gervig Carstensen<sup>1\*</sup>, Linnea Hornbech Larsen<sup>2</sup>, Christian Hassager<sup>2</sup>, Klaus Fuglsang Kofoed<sup>2,3</sup>, Jan Skov Jensen<sup>1</sup>, and Rasmus Mogelvang<sup>2</sup>

<sup>1</sup>Department of Cardiology, Gentofte Hospital, University of Copenhagen, Niels Andersens Vej 65, DK-2900 Copenhagen, Denmark; <sup>2</sup>Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; and <sup>3</sup>Department of Radiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

Received 22 October 2014; accepted after revision 11 May 2015; online publish-ahead-of-print 14 June 2015

#### Aims

To evaluate the prognostic value of global longitudinal strain (GLS) and basal longitudinal strain (BLS) with the knowledge of coexisting coronary pathology evaluated by multi-detector computed tomography (MDCT) coronary angiography.

#### Background

GLS and BLS are both sensitive markers of myocardial dysfunction and predictors of outcome in asymptomatic aortic stenosis. Aortic stenosis and ischaemic heart disease share risk factors and longitudinal function can be severely reduced in both conditions, why some of the previous findings of impaired regional longitudinal function in asymptomatic aortic stenosis could in fact be explained by silent ischaemic heart disease.



# Basal longitudinal strain predicts valve replacement in asymptomatic patients with AS

- www.imm.fr
  - Prospective follow-up of 104 asymptomatic patients with moderate—severe AS
    (aortic valve area <1.5 cm²). Longitudinal strain (GE Vingmed, Horten, Norway)</li>
  - Combined endpoint: indication for AVR and sudden cardiac death

	All patients (n = 104)	Patients with event-free survival (n = 61)	Patients with event (n = 43)	<i>P</i> -value
Demography, risk profile, and con	norbidity			
Age (years)	72 (±9)	72 (±9)	73 (±8)	0.49
Male gender	68% (71)	67% (41)	70% (30)	0.83
LVEF (%)	59 (55-66)	59 (56–67)	56 (54-61)	0.041 <sup>a</sup>
SVIndex (mL/m²)	42 (36-49)	41 (36–49)	42 (37-49)	0.68
LVMI (g/m <sup>2</sup> )	83 (72-98)	80 (70–99)	90 (73-99)	0.11
Peak gradient (mmHg)	43 (32-65)	38 (30–54)	52 (36-73)	< 0.001 <sup>a</sup>
Peak velocity (m/s)	3.3 (2.8-4.0)	3.1 (2.7–3.7)	3.6 (3.0-4.3)	< 0.001 <sup>a</sup>
Mean gradient (mmHg)	24 (18-40)	22 (16–34)	32 (23–47)	< 0.001 <sup>a</sup>
AVA (cm <sup>2</sup> )	0.90 (0.75-1.14)	0.98 (0.84-1.26)	0.80 (0.70-0.95)	< 0.001 <sup>a</sup>
AVAI (cm <sup>2</sup> /m <sup>2</sup> )	0.47 (0.39-0.60)	0.55 (0.41-0.63)	0.42 (0.36-0.49)	0.001 <sup>a</sup>
Moderate—AVA 1.0-1.5 cm <sup>2</sup>	36% (38)	49% (30)	19% (8)	0.001 <sup>a</sup>
Severe—AVA < 1.0 cm <sup>2</sup>	64% (66)	51% (31)	81% (35)	






# Basal longitudinal strain predicts valve replacement in asymptomatic patients with AS

www.imm.fr

- 104 asymptomatic patients with moderate—severe AS (aortic valve area <1.5 cm²)</li>
- Combined endpoint: indication for AVR and sudden cardiac death

#### **RESULTS:**

- Median follow-up: 2.3 years (1.7–3.6)
- No sudden cardiac death
- 43 patients (41%) met the endpoint of indication for AVR:
  - Symptoms (n=42)
  - LVEF <50% (n=1)






### Basal longitudinal strain predicts valve replacement in asymptomatic patients with AS

www.imm.fr


In contrast to GLS, BLS is a significant predictor of AVR in asymptomatic patients with AS





# Basal longitudinal strain <-13%

www.imm.fr



#### 29/11/2018-20:43:15

20.0


-20.0


		HR_ApLAX	53 bpm
GLPS_LAX	-21.1 %	FR_min	58 fps
GLPS_A4C	-17.8 %	PSD	65 msec
GLPS_A2C	-19.8 %		
GLPS_Avg	-19.5 <b>%</b>		
AVC_MAN	432 msec		





# Preserved LVEF vs. Impaired longitudinal strain, linked to myocardial fibrosis





24/09/2012-11:52:38

GLPS_LAX	-17.1 %	AVC_AUTO	378 msec
GLPS_A4C	-16.8 %	HR_ApLAX	89.9 bpm
GLPS_A2C	-14.5 %		
GLPS_Avg	-16.1 %		

Weidemann et al. Circulation. 2009; 120: 577-84






# The patient with asymptomatic AS

# What about current Guidelines?





2017 ESC/EACTS Guidelines for the management of valvular heart disease European Heart Journal. 2017; 38: 2739-91



# What is new in the 2017 Valvular Heart Disease Guidelines?



Changes in rec	ommendations	
2012	2017	
Indications for surgery in asymptomatic aortic stenosis		
IIb C Markedly elevated BNP levels.	Ila C Markedly elevated BNP levels (>threefold age- and sex-corrected normal range) confirmed by repeated measurements without other explanations.	
IIb C Increase of mean pressure gradient with exercise by >20 mmHg.	Taken out	
IIb C Excessive LV hypertrophy in the absence of hypertension.	Taken out	

2017 ESC/EACTS Guidelines for the management of valvular heart disease European Heart Journal. 2017; 38: 2739-91



### Indications for intervention in aortic **EACTS** stenosis and recommendations for the choice of intervention mode (continued)



Recommendations	Class	Level
c) Asymptomatic patients with severe aortic stenosis (refers only to pa eligible for surgical valve replacement)	tients	
SAVR is indicated in asymptomatic patients with severe aortic stenosis and systolic LV dysfunction (LVEF <50%) not due to another cause.	- 1	C
SAVR is indicated in asymptomatic patients with severe aortic stenosis and abnormal exercise test showing symptoms on exercise clearly related to aortic stenosis.	ı	C

2017 ESC/EACTS Guidelines for the management of valvular heart disease

**European Heart Journal. 2017; 38: 2739-91** 



# Indications for intervention in aortic stenosis and recommendations for the choice of intervention mode (continued)



Recommendations	Class	Level
SAVR should be considered in asymptomatic patients with severe aortic stenosis and abnormal exercise test showing fall in blood pressure below baseline.		ć
SAVR should be considered in asymptomatic patients with normal ejection raction and none of the above-mentioned exercise test abnormalities if the surgical risk is low and one of the following findings is present:  - very severe aortic stenosis defined by a V <sub>max</sub> >5.5 m/s,  - severe valve calcification and a rate of V <sub>max</sub> progression ≥0.3m/s/year,  - markedly elevated BNP levels (>threefold age- and sex-corrected normalrange) confirmed by repeated measurements without other explanations,  - severe pulmonary hypertension (systolic pulmonary artery pressure at rest >60 mmHg confirmed by invasive measurement) without other explanation.	lla	C

2017 ESC/EACTS Guidelines for the management of valvular heart disease

**European Heart Journal. 2017; 38: 2739-91** 

www o



# RAC sévère asymptomatique

- 1. <u>ECG d'effort</u> largement indiqué : faux asymptomatiques, Charge atteinte, %FMT, élévation de la PA systolique+++
- 2. Echographie d'effort : pas d'indication en pratique clinique (ESC-EACTS 2017): peu validé, études contradictoires, difficultés techniques
- 3. Risque de mort subite: 1,4% annuel, dans les 3 mois suivant la dernière consultation (2/3 des cas), aucun signe prémonitoire
- 4. Valeurs seuil à reconsidérer: RAC critique: Vmax > 5 m/s et dysfonction systolique VG: FEVG <55%
- 5. RVA CHIRURGICAL seul envisageable (ESC-EACTS 2017): durabilité >5 ans des prothèses TAVI inconnue (modèles ≈ 2015)






# AR: Clinical case #2

- Young man, 34 years old, strictly asymptomatic
- Height: 185 cm; weight: 70 kg
- Known BAV since infancy
- Referred for severe aortic regurgitation






# Anterior cusp prolapse






## Complete prolapse (Negative eH)






## Vertical jet -> anterior mitral leaflet






### Proximal aorta: not dilated






# Large aortic ring








### CW Doppler: Regurgitant jet






### PISA / Long-axis view




### ERO close to 30 mm<sup>2</sup>






## Very large extension of AR jet






## Cardiac output > 12 l/min







# Typical form of BAV (L-R)






# Prolapse of the conjoined cusp








### Commissural orientation = 160°






## LV End-diastolic diameter < 70 mm







## LV End-diastolic diameter <70 mm













## Clinical case: summary

- 34-year old man, strictly asymptomatic
- Typical form of bicuspid valve/ no calcification
- Prolapse of conjoined cusp/ No root dilatation
- Severe aortic regurgitation
- Severe LV dilatation
- Should this patient be operated on?



# Quelle prise en charge?

- A. Surveillance CLIN + Echo à 6 mois
- B. RVA chirurgical
- C. Chirurgie conservatrice (plastie valvulaire aortique)





# Quelle prise en charge?

- A. Surveillance CLIN + Echo à 6 mois
- B. RVA chirurgical
- C. Chirurgie conservatrice (plastie valvulaire aortique)





# **EACTS** Indications for surgery in severe aortic regurgitation



Recommendations	Class	Level
A. Severe aortic regurgitation	10	ă.
Surgery is indicated in symptomatic patients.	1	В
Surgery is indicated in asymptomatic patients with resting LVEF ≤50%.	1	В
Surgery is indicated in patients undergoing CABG or surgery of the ascending aorta or of another valve.	1	C
Heart Team discussion is recommended in selected patients* in whom aortic valve repair may be a feasible alternative to valve replacement.	ı	C
Surgery should be considered in asymptomatic patients with resting ejection fraction >50% with severe LV dilatation: LVEDD >70 mm, or LVESD>50 mm (or LVESD >25 mm/m <sup>2</sup> BSA in patients with small body size).	lla	В

<sup>\*</sup> Patients with pliable non-calcified tricuspid or bicuspid valves who have a type I (enlargement of the aortic root with normal cusp motion) or type II (cusp prolapse) mechanism of AR.

2017 ESC/EACTS Guidelines for the management of valvular heart disease **European Heart Journal. 2017; 38: 2739-91** 



## According to current Guidelines: No indication for surgery in this patient But where do these cutoff come from?

STAR, an armored space station with enough power to destroy an entire planet.

Sinister agents, Princess
Leia races home aboard her
starship, custodian of the
stolen plans that can save
her people and restore
freedom to the galaxy...





# Natural history of asymptomatic patients with chronic AR and normal LVEF

# 104 consecutive asymptomatic patients with severe chronic AR Inclusion: January 1973 to March 1988

TABLE 2. Risk Stratification Based on Kaplan-Meier Life Table Analysis of Measurements at Initial Study

Variable	Value	Likelihood of death, symptoms, or LV dysfunction
LV end-systolic dimension	>50 mm	19% per year
	40-49 mm	6% per year
	<40 mm	0% per year
LV end-diastolic dimension	≥70 mm	10% per year
	<70 mm	2% per year
LV ejection fraction response to exercise	Decrease >5%	12% per year
	Decrease 0-5%	4% per year
	Increase >0%	1% per year

LV, left ventricular.





# Do we have more recent data?





# Long-term outcomes in patients with aortic regurgitation and preserved LVEF

## Cleveland Clinic (January 2003 - December 2010)

- 1,417 patients (aged 54±16 years,75% men)
- Patients were asymptomatic(87%) or mildly symptomatic
- Grade ≥ 3/4 AR and preserved LVEF (>50%)
- 933 patients (66%) underwent AV surgery at 55 days (19 -435)
- Operative mortality: 2%


TABLE 2 Echocardiographic Variables	
LV ejection fraction, %	57 ± 4
LV end-diastolic diameter	
Nonindexed, cm	5.4 ± 0.9
Indexed, cm/m <sup>2</sup>	$2.7 \pm 0.6$
LV end-diastolic diameter	
≥6.5 cm	154 (11)
≥7.5 cm	18 (1.3)
LV end-systolic diameter	
Nonindexed, cm	$3.6 \pm 0.8$
Indexed, cm/m <sup>2</sup>	1.8 ± 0.4
LV end-systolic diameter ≥5 cm	50 (3.5)
iLVSD ≥2.5 cm/m <sup>2</sup>	93 (7)
Indexed left atrial area, cm²/m²	10.6 ± 3
Aortic valve morphology	
Trileaflet	877 (62)
Bicuspid	523 (37)
Unicuspid/quadricuspid	17 (1)





# Long-term outcomes in patients with aortic regurgitation and preserved LVEF

- AV surgery was associated with improved survival
- Survival of patients who underwent AV surgery: similar to age/sex-matched U.S. population
- Follow-up: 96% of deaths occurred in patients with indexed-LV-ESD <25 mm/m²</li>








# Long-term outcomes in patients with aortic regurgitation and preserved LVEF

# In the subgroup that did not undergo AV surgery:

- Patients with index-LV ESD <20 mm/m² had</li>
   excellent 5-year survival
- The risk of death significantly and continuously rose as index-LV-ESD increased beyond 20 mm/m<sup>2</sup>







## Mayo Clinic (2006-2017):


- 748 consecutive patients with Grade ≥3/4 chronic AR without prior heart surgery, AMI or overt CAD
- 387 patients (52%) were medically treated
- 361 patients (48%) underwent AVR

<b>TABLE 1</b> Baseline Characteristics and Echocardiographic Parameters in All Patients ( $N = 748$ )			
Age, yrs*	$58 \pm 17$		
Women	137 (18)		
Echo parameters			
LVEF, %	59 ± 8		
LVEF <50%	72 (10)		
LVESD			
Nonindexed, mm‡	40 ± 7		
>50 mm	49 (7)		
>55 mm	16 (2)		
LVESDi, mm/m <sup>2</sup> ‡	20 ± 4		
LVESDi >25 mm/m <sup>2</sup> *	74 (10)		
LVEDD			
Nonindexed, mm‡	60 ± 7		
>65 mm	151 (20)		
>75 mm	15 (2)		
Indexed, mm/m <sup>2</sup>	$30 \pm 4$		





FIGURE 2 Surgical Indications for 361 Patients With Aortic Valve Surgery





## **Surgery in 361 patients:**

- AV replaced (73%) or repaired (27%)
- Thoracic aorta procedures: 31%
- Mortality (30-day): 1%
- Patients with non-Class I indications for surgery had better post-operative survival









FIGURE 3 Kaplan-Meier Survival Curves Adjusted for Age, Sex, Charlson Comorbidity Index, and Symptoms in 3 Strata of LVESDi




AVR was associated with better survival in all patients: (A) LVESDi <20 mm/ $m^2$ , (B) 20-25 mm/ $m^2$  and (C) >25 mm/ $m^2$ 





5-year survival started to decrease in patients with LV index ESD >20 mm/m<sup>2</sup>

**CENTRAL ILLUSTRATION** Overall Survival by Left Ventricular End-Systolic Dimension Indexed for Body Surface Area in the Whole Cohort (Operated and Nonoperated Patients)







356 consecutive patients with <u>pure</u>, <u>isolated</u> ≥ <u>grade-3 chronic AR</u> operated on at the Clinique Universitaire St-Luc (Brussels, BE), between 1995 and 2014

## **Operative procedures:**

- AV repair (80%)
- Ross procedure (7%)
- Bioprosthetic AVR (9%)
- Mechanical AVR (4%)

Operative mortality = 1,1% (4 patients)

<u>Table 1</u> : Baseline demographic and clinical characteristics					
	Overall population				
Characteristics	Class I n=204	Class II n=73	No trigger n=79	P-Value	
Demographics					
Age (years)	55 ± 15	43 ± 15	49 ± 14	<0.001	
Male gender (n, %)	160 (78%)	69 (95%)	67 (85%)	0.006	
Weight (kg)	$80 \pm 17$	$84 \pm 17$	$82 \pm 17$	0.25	
Height (m)	$1.72 \pm 0.10$	$1.78 \pm 0.09$	$1.76 \pm 0.08$	<0.001	
Aortic pathology					
Bicuspid valve (%)	32	60	56	<0.001	
Type I dysfunction (%)	31	23	32	0.43	
Type II dysfunction (%)	40	60	49	0.008	
Type III dysfunction (%)	29	16	19	0.038	
Risk scores					
STS PROM (%)	$1.22 \pm 1.03$	$0.72 \pm 0.51$	$0.78 \pm 0.59$	<0.001	
Associated procedures					
CABG (%)	10	5	8	0.50	

(57%)


(21%)

(22%)






Class-I (symptoms/reduced LVEF) and Class-IIa triggers (end-systolic LV diameters) are associated with an increased risk of CV death or CHF








Class-IIb triggers (LV dilatation at end-diastole) do not result in an increased risk of mortality or an increased incidence of hospitalization for CHF








Increased risk of CV death or CHF as soon as LVEF falls below 55% or indexed LV end-systolic diameter >20 mm/m<sup>2</sup> (22 mm/m<sup>2</sup> in asymptomatic patients)









# Word of caution







# Survival implications of LV end-systolic diameter in MR due to flail leaflets (MIDA)

www.imm.fr

- 739 patients with MR due to flail leaflets (65±12 years, LVEF: 65± 10%)
- LVESD > 40 mm (22 mm/m²): Mortality risk increased linearly
- HR: 1.15, 95% CI: 1.04 to 1.27 per 1-mm increment






Figure 2 Association Between LVESD and the Risk of Overall Mortality Under Conservative Management








## LV End-systolic diameter = 44 mm












# Mechanical or Biologic Prostheses for Aortic and Mitral-Valve Replacement

AVR: 15-year mortality (45-54 years): 31% (Biologic) vs. 26% (Mechanical)



Significantly <u>lower</u>
<u>incidence of STROKE</u>
<u>with Bioprosthetic</u> vs.

Mechanical AV
in the 45-54 years
group






# Long-term results of external aortic ring annuloplasty for aortic valve repair

Long-term results of 232 consecutive patients (aged 50± 15 years) from the *Aortic Valve repair International Registry* (AVIATOR)

- Cusp repair in 75% of patients; 30-day operative mortality rate = 1.4%
- Mean FU: 40±38 months (0–146); actuarial survival rate at 7 years = 89.9%.







# Indications for surgery in severe aortic regurgitation



Recommendations	Class	Level
A. Severe aortic regurgitation	<del>,</del>	
Surgery is indicated in symptomatic patients.	1	В
Surgery is indicated in asymptomatic patients with resting LVEF ≤50%.	1	В
Surgery is indicated in patients undergoing CABG or surgery of the ascending aorta or of another valve.	1	C

Heart Team discussion is recommended in selected patients\* in whom aortic valve repair may be a feasible alternative to valve replacement.

1 6

Surgery should be considered in asymptomatic patients with resting ejection fraction >50% with severe LV dilatation: LVEDD >70 mm, or LVESD>50 mm (or LVESD >25 mm/m<sup>2</sup> BSA in patients with small body size).

Ila B

2017 ESC/EACTS Guidelines for the management of valvular heart disease

**European Heart Journal. 2017; 38: 2739-91** 

<sup>\*</sup> Patients with pliable non-calcified tricuspid or bicuspid valves who have a type I (enlargement of the aortic root with normal cusp motion) or type II (cusp prolapse) mechanism of AR.



# Indications for surgery in (A) severe aortic regurgitation and (B) aortic root disease (irrespective of aortic regurgitation severity) (continued)



Recommendations	Class	Level
B. Aortic root or tubular ascending aorta aneurysm (irrespective of the aortic regurgitation)	severi	ty of
Aortic valve repair, using the reimplantation or remodelling with aortic annuloplasty technique, is recommended in young patients with aortic root dilation and tricuspid aortic valves, when performed by experienced surgeons.	ı	C
Surgery is indicated in patients with Marfan syndrome, who have aortic root disease with a maximal ascending aortic diameter ≥50 mm.	Ĭ,	C

2017 ESC/EACTS Guidelines for the management of valvular heart disease European Heart Journal. 2017; 38: 2739-91



# Summary-1: Are we operating patients with chronic AR too late?

## Three large recent series (Total N>2 500) demonstrate that:

- Most patients with severe AR currently undergo surgery for class-I indications (2017 ESC-EACTS)
- Class-I and Class-IIa triggers are associated with an increased long-term risk of cardiovascular death or congestive heart failure
- Long-term survival (including postoperative) starts to decline a soon as:
  - LVEF is < 55%
  - Indexed LV end-systolic diameter is > 20-22 mm/m<sup>2</sup>





# Summary-2: Are we operating patients with chronic AR too late?

## **Caution: Retrospective studies**

- None of the previous (recent) studies was randomized
- 25-30% mortality 15 years after AV replacement, in patients aged 45-55 years
- AV repair might have better long-term results in these patients
- Current cutoffs might probably be revised, especially for young patients eligible for AV repair (as for primary MR)
- More robust data are certainly needed





# Incremental Prognostic Utility of Left Ventricular Global Longitudinal Strain in Asymptomatic Patients With Significant Chronic Aortic Regurgitation and Preserved Left Ventricular Ejection Fraction



Alaa Alashi, MD, Amgad Mentias, MD, Amjad Abdallah, MD, Ke Feng, MD, A. Marc Gillinov, MD, L. Leonardo Rodriguez, MD, Douglas R. Johnston, MD, Lars G. Svensson, MD, PhD, Zoran B. Popovic, MD, PhD, Brian P. Griffin, MD, Milind Y. Desai, MD

#### **ABSTRACT**

**OBJECTIVES** This study sought to examine the prognostic utility of left ventricular (LV) global longitudinal strain (GLS) in asymptomatic patients with ≥III+ aortic regurgitation (AR), an indexed LV end-systolic dimension of <2.5 cm/m<sup>2</sup>, and preserved left ventricular ejection fraction (LVEF).

**BACKGROUND** Management of asymptomatic patients with severe chronic AR and preserved LVEF is challenging and is typically based on LV dimensions.



# Incremental prognostic value of GLS in asymptomatic patients with chronic AR and preserved LVEF

#### www.imm.fr

<b>TABLE 1</b> Baseline Characteristics of the Study Population $(N=1,063)$			
Age, yrs	53 ± 16		
Male	813 (77)		
Race			
White	922 (87)		
African-American	64 (6)		
Asian	15 (1.4)		
Hispanic	18 (1.7)		
Other	43 (4)		
Body surface area, m <sup>2</sup>	$2.0 \pm 0.2$		
Hypertension	589 (55)		
Diabetes mellitus	57 (5)		
Hyperlipidemia	387 (36)		
Smoker	279 (26)		
Stroke	47 (4)		
Peripheral arterial disease	16 (2)		
Chronic renal failure	11 (1)		
Connective tissue disorder	37 (4)		
Society of Thoracic Surgeons score, %	$4.4 \pm 5.0$		

TABLE 3 Multivariate Cox Proportional Hazard Analysis for Predictors of Longer Term  Mortality in the Entire Study Population (Number of Deaths = 146)				
	HR (95% CI)	p Value		
STS score (for 1% increase)	1.51 (1.28-1.77)	< 0.001		
Indexed left ventricular end-systolic dimension (for every cm/m <sup>2</sup> increase)	0.50 (0.33-0.83)	<0.001		
Left ventricular global longitudinal strain (for every unit worsening)	1.11 (1.04-1.19)	0.003		
Right ventricular systolic pressure (for every 10 mm Hg increase)	1.33 (1.20-1.49)	< 0.001		
Aortic valve surgery	0.35 (0.25-0.50)	< 0.001		
Interaction between aortic valve surgery and indexed left ventricular end-systolic dimension	1.27 (1.14-3.15)	<0.01		


Higher iLV-ESD was paradoxically associated with lower long-term mortality, likely because patients with a higher iLV-ESD were more likely to be referred for AV surgery, which was associated with improved long-term survival.





# Incremental prognostic value of GLS in asymptomatic patients with chronic AR and preserved LVEF

FIGURE 5 Risk of Death, Based on LV-GLS in the Study Population as a Whole and in the Study Population Separated on the Basis of Undergoing Aortic Valve Surgery Versus Not



Progressive increase in mortality at GLS worse than ≈ 19%, in the entire study population and the non-surgical group. These findings need further validation.





## RAC sévère: indications opératoires de Classe II

RECOMMANDATIONS	Classe	NP
Un RVA est raisonnable en cas de RAC asymptomatique très sévère (Vmax ≥ 5.0 m/s) avec faible risque opératoire	lla	В
Un RVA est raisonnable en cas de RAC asymptomatique sévère avec diminution de la tolérance à l'effort ou chute tensionnelle lors du test d'effort	lla	В
Un RVA est raisonnable en cas de RAC modéré (Vmax = 3,0-3,9 m/s) si une chirurgie cardiaque est indiquée par ailleurs	lla	С





# Durability of transcatheter vs. surgical bioprosthetic aortic valves in patients at lower surgical risk

### **NOTION (Nordic Aortic Valve Intervention):**

 All-comer patients with severe AS and lower surgical risk randomized 1:1 to TAVR (n = 139) or SAVR (n = 135)

## 1/ Moderate/severe structural valve deterioration (SVD) :

- mean gradient ≥20 mm Hg
- increase in mean gradient ≥10 mm Hg
- more than mild intraprosthetic AR

2/ Bioprosthetic valve failure (BVF): valve related death, AV reintervention, or severe hemodynamic SVD

TABLE 1	Baseline Characteristics	of the Implanted	Cohort of the
NOTION 1	rial		

	TAVR (n = 139)	SAVR (n = 135)	p Value
Age, yrs	79.4 ± 4.9	78.8 ± 4.6	0.326
BMI, kg/m <sup>2</sup>	$26.6 \pm 4.3$	$26.6 \pm 4.1$	0.983
Male	52.5	53.3	0.893
NYHA functional class III/IV	46.4	46.3	0.986
STS score	$3.0 \pm 1.7$	$3.0 \pm 1.6$	0.882
STS score			0.832
<4%	82.7	81.5	House V
4%-10%	15.8	18.5	
>10%	1.4	0.0	
Logistics EuroSCORE II	$2.0 \pm 1.3$	$2.0 \pm 1.2$	0.906
Diabetes mellitus	17.3	20.7	0.463
Creatinine > 2 mg/dl	1.4	0.7	>0.999
Peripheral vascular disease	4.3	6.7	0.393
Prior stroke	5.8	9.6	0.228
Chronic lung disease	12.2	11.9	0.923
Permanent pacemaker	3.6	4.4	0.721
Atrial fibrillation/flutter	29.0	24.8	0.439

Values are mean ± SD or %

BMI = body mass index; NOTION = Nordic Aortic Valve Intervention; NYHA = New York Heart Association; SAVR = surgical aortic valve replacement; STS = Society of Thoracic Surgeons; TAVR = transcatheter aortic valve replacement.






# Durability of transcatheter vs. surgical bioprosthetic aortic valves in patients at lower surgical risk

www.imm.fr

Patients randomized to SAVR (27% Mosaic, 29% Epic, 24% Trifecta, 10% Perimount, and 10% Sorin Mitroflow) or TAVR (100% first-generation CoreValve) and followed annually







# Durability of transcatheter vs. surgical bioprosthetic aortic valves in patients at lower surgical risk

www.imm.fr

At 6 years, the rates of all-cause mortality were similar for TAVR (42.5%) and


SAVR (37.7%) patients (p. 0.58).

TABLE 3 Bioprosthetic Valve Dysfunction and Its Components Through 5 Years

	TAVR (n = 139)	SAVR (n = 135)	p Value
Bioprosthetic valve dysfunction	56.1	66.7	0.073
Components			
Structural valve deterioration	4.8	24.0	< 0.0001
Nonstructural valve deterioration	54.0	57.8	0.52
Thrombosis	0.0	0.0	NA
Endocarditis	5.8	5.9	0.95
Values are 9/			

Values are %.

Abbreviations as in Table 1.



There was no significant difference in bioprosthetic valve failure (BVF) between transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) through 6 years.





# Durability after AVR with the Mitroflow vs. the Perimount bioprosthesis

We compared 440 AVR with Mitroflow valves with 1953 AVR with CE pericardial valves implanted from 1999 to 2014 with regard to reoperation, reoperation for structural valve deterioration (SVD) and all-cause mortality.

		All valve sizes		
	All	CE Perimount	Mitroflow	
N	2393	1953	440	
Age	74.7 ± 6.8	74.4 ± 7.1	76.2 ± 5.5	0.00
Women	947 (39.6%)	622 (31.9%)	325 (73.9%)	0.00
Renal insufficiency	73 (3.1%)	63 (3.9%)	10 (3.2%)	NS
Diabetes	342 (14.3%)	285 (14.6%)	57 (12.9%)	NS
COPD	399 (16.7%)	334 (17.1%)	65 (14.8%)	NS
Previous surgery	73 (3.1%)	53 (2.7%)	20 (4.6%)	0.04
AVR + concomitant	1187 (49.6%)	968 (49.6%)	219 (49.8%)	NS
Endocarditis	70 (2.9%)	62 (3.2%)	8 (1.8%)	NS
Previous stroke	211 (8.8%)	165 (8.5%)	46 (10.5%)	NS
Peripheral artery disease	177 (7.4%)	149 (7.6)	28 (6.4%)	NS
Eject. Fract. 30-50%	769 (32.8%)	591 (30.3%)	177 (40.3%)	0.00
Eject. Fract. <30%	147 (6.5%)	130 (6.7%)	17 (3.9%)	0.03
Emergency	74(3.1%)	64 (3.3%)	10 (2.3%)	NS
EuroSCORE logistic	11.7 ± 12.5	11.4 ± 12.5	12.9 ± 12.3	0.01



# Durability after AVR with the Mitroflow vs. the Perimount bioprosthesis

- 10-year freedom from explant (for any cause) was higher for CE Perimount (98  $\pm$  0.7%) than for Mitroflow (95  $\pm$  1.4%, P < 0.01).
- 10-year freedom from explant due to SVD was higher for CE Perimount (100%) than for Mitroflow (96%) (P < 0.01).

